HK1181661A1 - Method for purifying pegylated erythropoietin - Google Patents
Method for purifying pegylated erythropoietinInfo
- Publication number
- HK1181661A1 HK1181661A1 HK13109018.4A HK13109018A HK1181661A1 HK 1181661 A1 HK1181661 A1 HK 1181661A1 HK 13109018 A HK13109018 A HK 13109018A HK 1181661 A1 HK1181661 A1 HK 1181661A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pegylated erythropoietin
- purifying pegylated
- purifying
- erythropoietin
- pegylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10176616 | 2010-09-14 | ||
| PCT/EP2011/065888 WO2012035037A1 (en) | 2010-09-14 | 2011-09-13 | Method for purifying pegylated erythropoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1181661A1 true HK1181661A1 (en) | 2013-11-15 |
Family
ID=43385653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13109018.4A HK1181661A1 (en) | 2010-09-14 | 2013-08-02 | Method for purifying pegylated erythropoietin |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20120197007A1 (pt) |
| EP (1) | EP2616101B1 (pt) |
| JP (1) | JP5735650B2 (pt) |
| KR (1) | KR101578586B1 (pt) |
| CN (1) | CN103118708B (pt) |
| BR (1) | BR112013005890B1 (pt) |
| CA (1) | CA2808748C (pt) |
| DK (1) | DK2616101T3 (pt) |
| ES (1) | ES2500048T3 (pt) |
| HK (1) | HK1181661A1 (pt) |
| MX (1) | MX342444B (pt) |
| PL (1) | PL2616101T3 (pt) |
| RU (1) | RU2566267C2 (pt) |
| SI (1) | SI2616101T1 (pt) |
| WO (1) | WO2012035037A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102816227A (zh) * | 2012-08-30 | 2012-12-12 | 深圳赛保尔生物药业有限公司 | 回收促红细胞生成素的方法 |
| DE102016210647B3 (de) | 2016-06-15 | 2017-09-14 | Schaeffler Technologies AG & Co. KG | Keilkupplung-Synchronisation |
| ES2841648T3 (es) * | 2016-07-15 | 2021-07-08 | Hoffmann La Roche | Procedimiento para purificar eritropoyetina PEGilada |
| US10695402B2 (en) | 2017-03-16 | 2020-06-30 | University Of Rochester | Erythropoietin for gastrointestinal dysfunction |
| EP3731871B1 (en) * | 2017-12-29 | 2023-10-04 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
| KR102497097B1 (ko) * | 2017-12-29 | 2023-02-06 | 에프. 호프만-라 로슈 아게 | 페길화 단백질 조성물의 제공 방법 |
| CN111801120A (zh) | 2017-12-29 | 2020-10-20 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
| WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| CA2045175C (en) | 1989-11-06 | 2003-03-18 | Arthur I. Skoultchi | Production of proteins using homologous recombination |
| DE779362T1 (de) | 1989-12-22 | 2001-04-05 | Applied Research Systems | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| DE4118912C1 (pt) | 1991-06-08 | 1992-07-02 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE225801T1 (de) | 1992-07-13 | 2002-10-15 | Bionebraska Inc | Verfahren zur modifizierung rekombinanter polypeptide |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| DK1157037T3 (da) | 1999-01-29 | 2003-11-24 | Hoffmann La Roche | GCSF-konjugater |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| ES2269366T3 (es) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
| US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| SI1543038T2 (sl) * | 2002-09-11 | 2020-12-31 | Genentech, Inc. | Čiščenje proteinov |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| WO2005021710A2 (en) | 2003-06-02 | 2005-03-10 | University Of Miami | Chimeric molecules and methods of use |
| SE0401951D0 (sv) | 2004-07-29 | 2004-07-29 | Amersham Biosciences Ab | Chromatography method |
| SG161210A1 (en) | 2004-12-22 | 2010-05-27 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
| WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
| AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
| AR067537A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
| WO2010034442A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Purification of erythropoietin |
| WO2010100220A1 (en) | 2009-03-05 | 2010-09-10 | Ascendis Pharma As | Interferon alpha carrier prodrugs |
-
2011
- 2011-09-13 SI SI201130253T patent/SI2616101T1/sl unknown
- 2011-09-13 CN CN201180044060.8A patent/CN103118708B/zh active Active
- 2011-09-13 BR BR112013005890-0A patent/BR112013005890B1/pt active IP Right Grant
- 2011-09-13 ES ES11754693.7T patent/ES2500048T3/es active Active
- 2011-09-13 KR KR1020137009524A patent/KR101578586B1/ko active IP Right Grant
- 2011-09-13 JP JP2013528645A patent/JP5735650B2/ja active Active
- 2011-09-13 DK DK11754693.7T patent/DK2616101T3/da active
- 2011-09-13 WO PCT/EP2011/065888 patent/WO2012035037A1/en active Application Filing
- 2011-09-13 PL PL11754693T patent/PL2616101T3/pl unknown
- 2011-09-13 EP EP11754693.7A patent/EP2616101B1/en active Active
- 2011-09-13 CA CA2808748A patent/CA2808748C/en active Active
- 2011-09-13 RU RU2013113724/15A patent/RU2566267C2/ru active
- 2011-09-13 MX MX2013002554A patent/MX342444B/es active IP Right Grant
- 2011-09-14 US US13/232,628 patent/US20120197007A1/en not_active Abandoned
-
2013
- 2013-08-02 HK HK13109018.4A patent/HK1181661A1/xx unknown
- 2013-11-26 US US14/090,927 patent/US20140163207A1/en not_active Abandoned
-
2016
- 2016-02-19 US US15/048,689 patent/US10273277B2/en active Active
-
2020
- 2020-09-17 US US17/024,477 patent/US20210094993A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5735650B2 (ja) | 2015-06-17 |
| BR112013005890B1 (pt) | 2022-02-08 |
| WO2012035037A1 (en) | 2012-03-22 |
| PL2616101T3 (pl) | 2015-01-30 |
| KR101578586B1 (ko) | 2015-12-17 |
| CA2808748A1 (en) | 2012-03-22 |
| US20120197007A1 (en) | 2012-08-02 |
| RU2566267C2 (ru) | 2015-10-20 |
| BR112013005890A2 (pt) | 2020-04-14 |
| MX342444B (es) | 2016-09-29 |
| MX2013002554A (es) | 2013-05-28 |
| US10273277B2 (en) | 2019-04-30 |
| SI2616101T1 (sl) | 2014-10-30 |
| DK2616101T3 (da) | 2014-08-04 |
| US20140163207A1 (en) | 2014-06-12 |
| US20210094993A1 (en) | 2021-04-01 |
| JP2013537208A (ja) | 2013-09-30 |
| EP2616101A1 (en) | 2013-07-24 |
| CN103118708A (zh) | 2013-05-22 |
| US20170008941A1 (en) | 2017-01-12 |
| EP2616101B1 (en) | 2014-07-09 |
| ES2500048T3 (es) | 2014-09-29 |
| CN103118708B (zh) | 2015-08-26 |
| KR20130073964A (ko) | 2013-07-03 |
| CA2808748C (en) | 2018-09-11 |
| RU2013113724A (ru) | 2014-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2608541T3 (pl) | Sposób dekodowania intra-predykcji | |
| HK1176946A1 (zh) | 純化免疫球蛋白溶液的方法 | |
| GB201001833D0 (en) | Method | |
| EP2613857A4 (en) | PROCESS FOR PURIFYING IMMUNOCONJUGATES OR ACTIVE POLYPEPTIDES | |
| EP2634142A4 (en) | PROCESS FOR THE PURIFICATION OF CHLOROSILANES | |
| GB201007353D0 (en) | Method | |
| SI2598516T1 (sl) | Postopek za čiščenje proteinov | |
| HU1000330D0 (en) | Novel method | |
| HK1181661A1 (en) | Method for purifying pegylated erythropoietin | |
| GB201007354D0 (en) | Method | |
| PL2632586T3 (pl) | Sposób wytwarzania katalizatora | |
| EP2727930A4 (en) | PROCESS FOR CLEANING PROTEINS | |
| GB201011513D0 (en) | Method | |
| GB201004759D0 (en) | Method | |
| ZA201302330B (en) | Method for purifying water | |
| EP2743259A4 (en) | PROCESS FOR CLEANING (S) -OXIRACETAM | |
| GB201012148D0 (en) | Method | |
| IL209654A0 (en) | Method for purifying erythropoietin | |
| GB201006306D0 (en) | Method | |
| EP2743258A4 (en) | PROCESS FOR PURIFYING LEVO-OXIRACETAM | |
| GB201010855D0 (en) | Method | |
| EP2762486A4 (en) | PROCESS FOR PURIFYING PROTEIN | |
| GB201012784D0 (en) | Method | |
| GB201007207D0 (en) | Method | |
| GB201007522D0 (en) | Method |